OraSure

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 -23.50%Q3 2024 -1.17%Q2 2024 +2.60%Q1 2024 -8.84%Q4 2023 +10.27%Q3 2023 +4.88%Q2 2023 +31.71%Q1 2023 +9.16%Q4 2022 +10.38%Q3 2022 +0.68%Q2 2022 +28.27%Q1 2022 -8.87%Q4 2021 -1.27%Q3 2021 -4.88%Q2 2021 +1.18%Q1 2021 +4.96%Q4 2020 -2.30%Q3 2020 -15.62%Q2 2020 -32.14%Q1 2020 +6.14%Q4 2019 -6.70%Q3 2019 -3.15%Q2 2019 -3.27%Q1 2019 -8.00%Q4 2018 -25.52%Q3 2018 -8.69%Q2 2018 -0.60%Q1 2018 -15.45%Q4 2017 -12.80%Q3 2017 -30.33%Q2 2017 +13.52%Q1 2017 +16.89%Q4 2016 +18.93%Q3 2016 -0.14%Q2 2016 +4.65%Q1 2016 -6.60%Q4 2015 +14.66%Q3 2015 +0.38%Q2 2015 +7.00%Q1 2015 -12.26%Q4 2014 -11.90%Q3 2014 +2.85%Q2 2014 -7.66%Q1 2014 -9.19%Q4 2013 +9.48%Q3 2013 -0.31%Q2 2013 +10.18%Q1 2013 -0.42%Q4 2012 -12.36%Q3 2012 -16.37%Q2 2012 -7.08%Q1 2011 +4.98%Q1 2012 -5.91%Q4 2011 +4.65%Q3 2011 -5.61%Q2 2011 -12.55%Q4 2010 -12.55%Q3 2010 +6.64%Q2 2010 -6.97%Q1 2010 -15.40%

May 10, 2022

•

Mar 31, 2022

OraSure Q1 2022 Earnings Report

Reported record revenue and growth in non-COVID revenue.

Key Takeaways

OraSure Technologies reported a record revenue of $67.7 million for Q1 2022, a 16% increase year-over-year, with a 21% growth in non-COVID revenue. The company scaled InteliSwab® production, improved manufacturing efficiency, and saw strong demand for molecular kits.

Net revenues reached a record $67.7 million, up 16% year-over-year.

Diagnostic business unit revenue grew 163%, driven by InteliSwab®.

Molecular Solutions business unit revenue declined 33%, but non-COVID revenues grew 28%.

Gross margin was 36%, impacted by InteliSwab® manufacturing costs and product mix.

Total Revenue

$67.7M

Previous year: $58.6M